Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;45(3):319-33.
doi: 10.1002/mus.22329. Epub 2011 Dec 15.

Consensus treatment recommendations for late-onset Pompe disease

Edward J Cupler  1 , Kenneth I Berger, Robert T Leshner, Gil I Wolfe, Jay J Han, Richard J Barohn, John T Kissel; AANEM Consensus Committee on Late-onset Pompe Disease
Affiliations

Consensus treatment recommendations for late-onset Pompe disease

Edward J Cupler et al. Muscle Nerve. 2012 Mar.

Abstract

Introduction: Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders.

Methods: Objective is to propose consensus-based treatment and management recommendations for late-onset Pompe disease.

Methods: A systematic review of the literature by a panel of specialists with expertise in Pompe disease was undertaken.

Conclusions: A multidisciplinary team should be involved to properly treat the pulmonary, neuromuscular, orthopedic, and gastrointestinal elements of late-onset Pompe disease. Presymptomatic patients with subtle objective signs of Pompe disease (and patients symptomatic at diagnosis) should begin treatment with enzyme replacement therapy (ERT) immediately; presymptomatic patients without symptoms or signs should be observed without use of ERT. After 1 year of ERT, patients' condition should be reevaluated to determine whether ERT should be continued.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Timeline for Pompe disease: 75 years from description to availability of disease-modifying agent. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 2
FIGURE 2
Pathophysiology of Pompe disease. GAA, acid alpha-glucosidase; UDP, uridine diphosphate. Based on Raben et al. with permission. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 3
FIGURE 3
Multidisciplinary approach for the management and care of Pompe disease. Based on Kishnani et al. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 4
FIGURE 4
Changes from baseline in distance walked and in forced vital capacity according to study group. Based on van der Ploeg et al. (A) and van der Ploeg et al. (B) with permission. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
See this image and copyright information in PMC

References

    1. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i–iv. 1–88. - PubMed
    1. Pompe JC. Over idioptische hypertrophie van het hart. Ned Tidschr Geneeskd. 1932;76:304–311.
    1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144(suppl):S35–S43. - PubMed
    1. Cori GT. Biochemical aspects of glycogen deposition disease. Mod Probl Paediat. 1957;3:344–358. - PubMed
    1. Hers HG. Alpha-glucosidase deficiency in generalized glycogen-storage disease (Pompe’s disease) Biochem J. 1963;86:11–16. - PMC - PubMed

Publication types

MeSH terms